Top Markets
Coin of the day
Tvardi Therapeutics, Inc. Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD
Rank in Stocks #30249
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Share Price
$1.88
Last synced: 2026-08-18
Market Cap
$17.59M
Change (1 day)
0.81%
Change (1 year)
-92.40%
Country
US
Trade Tvardi Therapeutics, Inc. (TVRD)

Category

Stock price history for Tvardi Therapeutics, Inc. (TVRD)
Highest end of day price: $1.83 on 2026-08-01

Lowest end of day price: $17.54 on 2025-04-01
Stock price history of Tvardi Therapeutics, Inc. from 2025 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 100.99%
2025 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$527.89 35.09%
US
$996.61 51.72%
NL
$115.26 -20.82%
AU
$735.86 6.07%
CH
$1.06K -5.95%
KR